The efficiency of treatment in patients with uterine-confined endometrial cancer

Aim: To present our experience regarding the efficiency of treatment in patients with uterine-confined endometrial cancer.

Patients and methods: 775 patients with uterine-confined endometrial cancer (UCEC) were treated between July 1985 and June 2000 in the Krakow Branch of Sklodowska Memorial Institute.

Results: Among the 775 patients, 5-year disease-free survival was observed in 82.8% patients; 96% patients with low risk of disease recurrence, 93.6% patients with intermediate risk and 78.3% patients with high risk survived five years with no evidence of disease. In the group with a high-risk disease recurrence rate, 5-year disease-free survival was statistically higher among patients treated with adjuvant brachytherapy plus external beam radiotherapy (EBRT) in comparison to patients treated with adjuvant brachytherapy (BRT) alone (82.4% vs 72.1%).

Conclusions: The recommended treatment in patients with high and moderate differentiation of UCEC with FIGO Stage IA is surgery alone. Surgery with adjuvant EBRT in the group of patients with intermediate risk of cancer recurrence allows over 90% of patients to be cured. In the group of patients with a high risk of disease recurrence adjuvant BRT with EBRT is statistically more efficient in comparison to BRT alone.

Uterine-confined endometrial cancer; Treatment results

[1] Akcerman I., Malone S., Thomas G. et al.: "Endometrial carcinoma- relative effectiveness of adjuvant irradiation vs therapy reserved for relapse". Gynecol. Oneal., 1966, 60, 177.

[2] Anderson J. M., Stea B., Hallum A. V. et al.: "High-dose-rate postoperative vaginal cuff irradiation alone for stage 1B and IC endometrial cancer". Int. J. Radiat. Oneal. Biol. Phys., 2000, 46, 417.

[3] Backe J., Gassel A. M., Hauber K. et al.: "P53 protein in endometrial cancer is related to proliferative and prognosis but not expression of p23 protein". Int. J. Gynecol. Pathol., 1997, 16, 361.

[4] Barakat R.R.: "Contemporary issues in the management of endometrial cancer". Ca Cancer J. Clin., 1988, 48, 299.

[5] Bolla M., de Cornulier J., Berland E. et al.: "Pathological prognostic factors in a series of 137 stage I TNM/UICC endometrial carcinomas". Radiother. Oneal., 1999, 53, 209.

[6] Bonatz G., Luttes J., Hamann S. et al.: "Immunohistochemical assessment of p 170 provides prognostic information in endometrial carcinoma". Histopathology, 1999, 34, 43.

[7] Bonnier P., Torre J.D., Khouzani A., Piana L.: "Traitement ch1rurgical des cancers de l'endometre aux stades I et II cliniques". Bull. Cancer/Radiother., 1992, 709, 475.

[8] Cardenes H., Randall M. E.: "Clarity and confusion regarding adjuvant radiation therapy in early endometrial cancer". Gynecol Oneal., 1999, 75, 1.

[9] Carey M.S., O'Connell G.J., Johanson C.R. et al.: "Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical Stage I adenocarcinoma of the endometrium". Gynecol. Oneal., 1995, 57, 138.

[10] Carl U.M., Bahnsen J., Edel B., Chandra A.:'The value of postoperative radiation therapy in FIGO Stage I and II endometrial cancer". Strahlenther. Onkol., 1995, 17, 322.

[11] Charra-Brunaud C., Peiffert D., Hoffstetter S. et al.: "Curietherapie vaginal postoperatoire des adenocarcinomes de I'endometre a bas debit de dose". Cancer Radiother., 1998, 2, 34.

[12] Chassagne D., Sismondi P. Horiot J. C. et al.: "A glossary for reporting complications of treatment in gynecological cancers" Radiother. Oneal., 1993, 26, 195.

[13] Corn B.W., Lanciano R.M., D'Agostino R. et al.:'The relationship of local and distant failure from endometrial cancer: defining a clinical paradigm". Gynecol. Oneal., 1997, 66, 414.

[14] Cox. D.R.: "Regression models and life-tables (with discussion)" J. R. Stat. Soc. B., 1972, 34, 187.

[15] Creasman W.T., Morrow C.P., Bundy B.N. et al.: "Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study". Cancer, 1987, 60, 2035.

[16] Creutzberg C.L., van Putten W.L., Koper P.C. M. et al.: "Surgery and postoperative radiotherapy versus surgery alone for patients with stage-] endometrial carcinoma: multicentre randomized trial". Lancet, 2000, 355, 1404.

[17] Einhorn J.: "Radiotherapy for cancer. A critical review of the literature". Acta Oneal., 1997, 35 (suppl. 7), 81.

[18] Elliott P., Green D., Coates A. et al.: "The enicacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer". int. J. Gynecol. Cancer, 1994, 4, 84.

[19] Eltabbakh G.H., Moore AD.: "Survival of women with surgical stage II endometrial cancer". Gynecol. Oneal., I 999, 74, 80.

[20] FIGO stages - 1988 revision (announcements). Gynecol. Oncol., 1989, 35, 125.

[21] Garcia-Domenech R.V., Inesta J.M., Asins E. et al.: "Prognostic factors in endometrial carcinoma: risk groups and adjuvant radiotherapy". Eur. J. Gynaecol. Oneal., 1997, 18, 164.

[22] Greven K.M., Corn B., Cose D. et al.: "Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation". int. J. Radial. Oneal. Biol. Phys., 1997, 39, 413.

[23] Greven K.M., D'Agostino R.B. Jr., Lanciano R.M., Corn B.W.: "Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine - confined endometrial cancer?". Int. J. R呻at. Oneal. Biol. Phys., 1998, 42, 101.

[24] Greven K.M.: "Tailoring radiation to the extent of disease for uterine - confined endometrial cancer". Semin. Radiat. Oneal., 2000, 10, 29.

[25] Hachisuga T., Kaku T., Fukuda K. et al.: "The grading of lymphovascular space invasion in endometrial carcinoma". Cancer, 1999, 86, 2090.

[26] Huguenin P., Baumert B., Lutolf U.M. et al.: "Curative radiotherapy in elderly patients with endometrial cancer. Patterns of relapse, toxicity and quality of life". Strahlenther. Onkol., 1999, 175, 309.

[27] Irvin C., Levin W., Fyles A. et al.: "The role of adjuvant radiotherapy in carcinoma of the endometrium - results in 550 patients with pathologic Stage I disease". Gynecol. Oncol., 1998, 70, 247.

[28] Jareczek-Fossa B.A.: "Postoperative irradiation in endometrial cancer: still a matter of controversy". Cancer Treat. Rev., 2001, 27, 19.

[29] Jareczek-Fossa B., Badzio A., Jassem J.: "Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure". Int. J. Gynecol. Cancer, 1999, 9, 285.

[30] Kloetzer K. H., Gunther R., Wendt T.: "The vaginal stump recurre nee rate in endometrial carcinoma in relation to the target volume of postoperative HDR - afterloadin brachyterapy". Strahlenther. Onkol., 1997, 173, 13.

[31] Kucera H., Vavra N., Weghaupt K.: "Benefit external irradiation in pathologic Stage I endometrial caicinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors". Gynecol. Oncol., 1990, 38, 99.

[32] Larson D.M., Broste S.K., Krawisz B.R.: "Surgery without radiotherapy for primary treatment of endometrial cancer". Ohstet. Gynecol., 1998, 91, 355.

[33] Lukes A.S.,K ohler M.F.,P ieper C.F. et al.: "Multivariate analysis of DNA ploidy, p53, and HER-2/neu prognostic factors in endometrial cancer". Cancer, 1994, 73, 2380.

[34] Lybeert M.L., van Putten W.L.J., Brdlman H.A.M., Coebergh J.N.N.: "Postoperative radiotherapy for endometrial c打cinoma. Stage I. Wide variation in referral patterns but no effect on longterm survival in a retrospective study in southeast Netherlands". Eur. J. Cancer, 1988, 34, 586.

[35] Morrow C.P., Budy B.M., Kurman R.J. et al.: "Relationship between surgical-pathological risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study". Gynecol. Oncol., 1991, 40, 55.

[36] Nag S., Ericksen B., Parikh S. et al.: "The American Brachytherapy Society recommendation for high-dose rate brachytherapy for carcinoma of the endometrium". Int. J. Radiat. Oncol. Biol. Phys., 2000, 48, 779.

[37] Naumann R.W., Higgins R.V., Hall J.B.: "The use of adjuvant radiation therapy by members of the Society of Gynecology Oncologists". Gynecol. Oneal., 1999, 75, 4.

[38] Pavy J.J., Denekamp J., Letscher! J. et al.: "Late effects toxicity scoring: the SOMA scale". Radiother. Oneal., 1995, 35, 17.

[39] Peiffert D., Hoffstetter S., Charra-Brunaud C.: "Curietherapie des cancers de l'endometre". Cancer Radiother., 2003, 7, 121.

[40] Perno! M., Hoffstetter S., Peiffer! D. et al.: "Pre-operative, postoperative and exclusive irradiation of endometrial adenocarcinoma. Strahlenther". Onkol., 1994, 17, 313.

[41] Peto R.,P ike H.G.,A rmitage P. et a!.: "Design and analysis of randomized clinical trials requiring prolonged observation of each patients I. Analysis and examples". Br. J. Cancer, 1977, 35, 1.

[42] Roberts J.A., Brunetto V.L., Key H.M. et al.: "A phase III randomized study of surgery vs. surgery plus adjunctive radiation therapy in intermediate-risk endometrial carcinoma". Gynecol. Oncol., 1998, 68, 135..

[43] Rose P.G.: "Endometrial carcinoma". N. Engl. J. Med., 1996, 335, 640.

[44] Rush S., Gal D., Potters L. et al.: "Pelvic control following external beam irradiation for surgical stage I endometrial adenocarcinoma". Int. J. Radiat. Oncol. Biol. Phys., 1995, 33, 851.

[45] Salvesen H.B., Iversen C.E., Akslen L.A.: "Prognostic significance of angiogenesis and K-67, p53 and p21 expression: a population-based endometrial carcinoma study". J. Clin. Oncol., 1999, 17, 1382.

[46] Thomas L., Batailland A., Bremond A. et al.: "Standards, Options et Recommendations pour la radiotherapie des patients atteintes de cancer de l'endometre". Cancer Radiother., 2001, 5, 163.

[47] Weiss E., Hirnle P., Arnold-Bofinger H. et al.: "Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma patients of relapse and side effects following low-dose therapy". Gynecol. Oncol., 1998, 71, 72.

[48] Weiss E., Hirn le P., Arnold-Bofinger H. et al.: "Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma Stage I and II." Radiother. Oneal., 1999, 53, 37.

[49] Zaino R.J., Kurman R.J., Kiana K.L., Morrow P.C.: "Pathologic models to predict outcome for women with endometrial adenocarcinoma". Cancer, 1996, 77, 1115.